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Multiple models of human neuropsychiatric pathologies have been generated during the last decades which frequently use chronic
dosing. Unfortunately, some drug administrationmethodsmay result in undesirable effects creating analysis confounds hampering
model validity and preclinical assay outcomes. Here, automated analysis of floating behaviour, a sign of a depressive-like state,
revealed that mice, subjected to a three-week intraperitoneal injection regimen, had increased floating. In order to probe an
alternative dosing design that would preclude this effect, we studied the efficacy of a low dose of the antidepressant imipramine
(7mg/kg/day) delivered via food pellets. Antidepressant action for this treatment was found while no other behavioural effects
were observed. We further investigated the potential efficacy of chronic dosing via food pellets by testing the antidepressant
activity of newdrug candidates, celecoxib (30mg/kg/day) and dicholine succinate (50mg/kg/day), against standard antidepressants,
imipramine (7mg/kg/day) and citalopram (15mg/kg/day), utilizing the forced swim and tail suspension tests. Antidepressant effects
of these compounds were found in both assays. Thus, chronic dosing via food pellets is efficacious in small rodents, even with a
low drug dose design, and can prevail against potential confounds in translational research within depression models applicable to
adverse chronic invasive pharmacotherapies.
1. Introduction
The challenge to propose new powerful therapeutics for neu-
ropsychiatric disorders, including antidepressants, has raised
important questions regarding the efficiency of preclinical
approaches currently being used [1–3]. Numerous limitations
of the models of human neuropsychiatric pathologies have
been intensively discussed during the last years [4–6]. Apart
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from a general problemof translational research, basic practi-
cal issues with animalmodels of neuropsychiatric conditions,
however seemingly trivial, can essentially affect the validity of
preclinical models, yet these can be addressed and resolved.
Aswith translationalmodels in small rodents, these issues
concern laboratory and procedural settings in animal studies.
A number of experimental conditions have been shown to
result in potential confounds for the practical application of
animal models. The principals of these factors are commonly
considered to include the circadian phase of manipulations
[7, 8], cage enrichment [9–11], lighting conditions [12, 13],
handling [14–16], vibration [17], the adverse taste of food
or water [18, 19], and presence of and manipulations by an
experimenter [20, 21]. They are sometimes believed to result
in the remarkable variability in results that are extensively
reported by the literature [18, 22–24]. The method and
duration of dosing of experimental animals are one of the
important sources of such confounds [25–27].
Various types of invasive treatments in rodents were
shown to induce pain, inflammation, and distress, despite the
proper use of standardizedmethods of application, especially
when prolonged dosing is employed [28–30]. Obviously, this
raises issues that concern not only the quality of studies, in
which such dosing methods are used, but also animal welfare
and ethical aspects. Nonetheless, in many cases, long and
invasive drug administration to small rodents is problematic
to avoid. This often applies, for instance, when non-water-
soluble compounds have to be chronically administered,
for example, during experimental conditions for which the
induction of a desirable syndrome in an animal and/or
the occurrence of the therapeutic drug’s effect require a
long time. The latter experimental situations are particularly
typical for testing drugs in rodent models of depression
where, for example, the induction of some key elements
of depressive syndrome may take 2–12 weeks [24, 31, 32]
and the occurrence of an antidepressant’s effect, with most
of the classical antidepressants, develops after 3-4 weeks of
treatment [31, 33, 34].
In order to avoid the negative effects of chronic invasive
dosing on overall animal welfare and experimental outcomes
from standardmodels of depression, we evaluated the efficacy
of drug delivery via food pellets in mice. First, we studied the
effects of a three-week daily intraperitoneal vehicle injection
in the mouse forced swim test, a common scheme of testing
for the antidepressant-like effects of various treatments [32,
34, 35]. As this manipulation resulted in an increase of
floating scores, a measure of “behavioural despair,” indicating
a “prodepressant” effect of daily intraperitoneal injections for
the experimental animals, we probed an alternative way of
dosing using food pellets.
Though drug delivery with voluntarily consumed food is
one of the common methods of dosing, its use in laboratory
research is quite limited. Meanwhile, in many cases, this
mode of pharmacological treatment is seen as advantageous
because it enables the maintenance of a steady blood concen-
tration for the drug, in contrast to bolus drug administration.
However, it is sometimes viewed as insufficiently reliable due
to its reliance on food intake and the variable bioavailability of
some compounds depending on their delivery route [36, 37].
However, given that, in a reasonable proportion of the
experimental situations, the consummatory behaviour of
laboratory animals is not altered and the standard pharmaca,
whose bioavailability and metabolism are well known not to
be sensitive to the treatment method, are used, dosing with
the voluntary intake of food pellets can probably be exploited
much more frequently. Apart from the obvious benefits
of animal wellbeing, the delivery of investigational drugs
with food pellets can increase the validity of translational
models as it simulates a human equivalent therapeutic dosing
route.
In this study, we first used, via food pellets, a low dose
of a classical antidepressant reference drug, imipramine
(7mg/kg/day), for which chronic administration via drink-
ing water for 3 weeks was recently reported to evoke an
antidepressant effect in a model of stress-induced anhedonia
[38]. A low dose of antidepressant was selected because we
sought to evaluate the usefulness of this dosing method at
the lowest possible dosage limit which is used in other means
of drug administration and because imipramine may exert
side-effects when applied in higher concentrations [6]. The
effects of imipramine delivered with self-made food pellets
were tested in the forced swim test as well as, in order to
exclude potential nonspecific effects of treatment, in a battery
of behavioural tests including dark/light box, O-maze, novel
cage, open field, and two-bottle sucrose test. Finally, to verify
the applicability of this defined dosing method with food
pellets, we tested the effects of new potential antidepressants:
celecoxib, a non-water-soluble compound, at the dose of
30mg/kg/day, which was selected based on previously pub-
lished data [39, 40], and dicholine succinate whose dose was
applied at 50mg/kg/day based on previous results [42], in the
forced swim and tail suspension tests. Imipramine, applied
at 7mg/kg/day [6, 36, 41, 42], and citalopram, 15mg/kg/day
[6, 33, 38], were used as pharmacological references.
2. Materials and Methods
2.1. Animals and Housing. Three-month-old C57BL/6Nmale
mice were supplied by Instituto Gulbenkian de Cieˆncia,
Oeiras, Portugal, and housed individually in standard lab-
oratory conditions under a reverse 12:12 h cycle (lights on
at 21:00). Behavioural tests took place from the onset of
the dark phase of the light cycle (9:00 h). The testing was
carried out in a dark quiet room in morning hours. All
procedures were in accordance with the European Union’s
Directive 2010/63/EU, Portuguese Law-Decrees DL129/92
(July 6th), DL197/96 (October 16th), and Ordinance Port.
131/97 (November 7th). This project was approved by the
Ethical Committee of the New University of Lisbon.
2.2. Study Flow with Chronic Intraperitoneal Injections. This
study used a broadly applied treatment, in small rodents, of
chronic intraperitoneal injections [30]. We have chosen to
expose mice to a three-week daily intraperitoneal injections
of NaCl at volume 0.01mL/g body weight (for scheme of
study flow, see Figure 1(a)). Controlmice were not treated but
handled daily. Starting from the next day after this period,
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Figure 1: Experimental design. (a) Schematic timeline of studies with vehicle injections, chronic delivery with food pellets of (b) imipramine
and (c) new drug candidates to antidepressants experiments. i.p.: intraperitoneal injection of a vehicle; FST: forced swim test; TST: tail
suspension test; DLB: dark-light box; OM: O-maze; NCT: novel cage test; OF: open field; ST: sucrose test; d: days.
mice were tested in the two-day forced swim test as previ-
ously described [38, 41]. Behavioural data were scored using
Noldus EthoVision XT 8.5 (Noldus Information Technology,
Wageningen, Netherlands). Number of mice per group is
indicated in figure legend.
2.3. Study Flow with Chronic Imipramine Delivery via Food
Pellets. As a next step, we exposed mice to self-made food
pellets that contained imipramine for four weeks. Prior to
starting treatment, animals were balanced upon body weight.
The calculation of the used concentration of imipramine in
food pellets was based on a daily food intake of experimental
mice that constituted 2.89 ± 0.26 g and a desirable dosage
of 7mg/kg/day. The selection of this dose was based on
previously obtained data that showed the efficacy of the dose
[38] and a lack of such with chronic imipramine delivery via
drinking water at a dose of 2.5mg/kg in mice. Control mice
received a regular diet. Before the start and after four weeks
of dosing, all mice were tested in the sucrose preference test,
O-maze test, and the dark/light box, as described elsewhere
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[43, 44]. After two and four weeks of dosing, locomotor
activity of all mice was studied in the novel cage and open
field tests, as described elsewhere [41, 42, 44]. At the end of
behavioural testing, a two-day forced swim test with 6min
sessions was performed as previously described ([38, 41]; for
scheme of study flow, see Figure 1(b)). Number of mice per
group is indicated in figure legend.
2.4. Study Flow with Chronic Delivery via Food Pellets of
New Candidates to Antidepressants. Next, we subjected mice
to food pellets that contained imipramine, citalopram, cele-
coxib, or dicholine succinate for four weeks. Prior to starting
treatment, animals were balanced upon body weight. The
latter two drugs are regarded as compounds with potential
antidepressant activity [39, 40, 42]. The calculation of drug
concentrations was based on daily food intake of experimen-
tal mice, and desirable doses were 7mg/kg/day, 15mg/kg/day,
30mg/kg, and 50mg/kg, respectively. Control mice received
regular diet. A two-day tail suspension test and a two-day
forced swim test were carried out during four consecutive
days after the termination of the dosing period, as described
elsewhere [41, 43] (for scheme of study flow, see Figure 1(c)).
Number of mice per group is indicated in figure legend.
2.5. Preparation of Pellets. Imipramine hydrochloride (Sig-
ma-Aldrich, Munich, Germany), citalopram (Lundbeck,
Copenhagen, Denmark), or celecoxib (Pfizer, Berlin, Ger-
many) was added to commercial chow (Mucedola SRL,
Milan, Italy) that was turned to powder by a blender. Small
amounts of distilled water were added, and food pellets of
a similar size to commercial pellets were formed and dried
overnight (16 h) at 60∘. New pellets were prepared twice a
week in order to refresh the food supply of experimental
groups. The content of drugs was adjusted to the dose
indicated above andwas based on the consumption of normal
diet that was averaged over 3 days. Food pellets containing
dicholine succinate (Buddha Biopharma Oy Ltd., Helsinki,
Finland) were prepared in a similar way, using a 7% solution
of the compound; the content of drug was adjusted to the
abovementioned daily dose of this drug.
2.6. Behavioural Tests
2.6.1. Forced SwimTest. ThePorsolt forced swim test has been
used as described elsewhere [38, 41]. Mice were subjected
to two 6min swimming sessions spaced 24 h apart in a
transparent cylinder (Ø 17 cm) filledwithwater (+23∘C,water
height 13 cm, height of cylinder 20 cm, and illumination
intensity 25 Lux). Floating behaviour was defined by the
absence of any directed movements of the animals’ head and
body and was scored with Noldus EthoVision XT 8.5 (Noldus
Information Technology, Wageningen, Netherlands). Using
this method, the latency of the first episode of floating and
the duration of floating behaviour were recorded during
the 6min swimming session on Day 1 and Day 2 of the
test. Latency to begin floating was scored as time between
introduction of the animal into the pool and the first moment
of complete immobility of the entire body for a duration of
>3 seconds. The total time spent floating, number of floating
episodes, mean velocity, and distance moved were scored for
the entire duration of the test using posttest video footage.
2.6.2. Dark/Light Box. The dark/light box (Technosmart,
Rome, Italy) consisted of two plexiglass compartments, one
black/dark (15 cm × 20 cm × 25 cm) and one lit (30 cm
× 20 cm × 25 cm), connected by a tunnel. Anxiety-like
behaviour was assessed by earlier validatedmeasures [41, 43].
Mice were placed into the dark compartment, from where
they could visit the lit box, illuminated by light of 25 Lux
intensity.The latency of the first exit to the light compartment,
the total duration of time spent in the lit box, and the number
of visits to this anxiety-related compartment were scored by
visual observation over 5min.
2.6.3. Elevated O-Maze. The apparatus (Technosmart, Rome,
Italy), which consisted of a circular path (runway width
5.5 cm, diameter 46 cm), was placed 50 cm above the floor.
Two opposing arms were protected by walls (height 10 cm),
and the illumination strength was 25 Lux. The apparatus
was placed on a dark surface in order to reduce reflection
and maintain control over lighting conditions during testing.
Anxiety-like behaviour was assessed using previously vali-
dated parameters [38, 44]. Mice were placed in one of the
closed-arm compartments of the apparatus. The latency of
the first exit to the anxiety-related open compartments of
the maze, the total duration of time spent therein, and the
number of exits to the open arms were scored during a 5min
observation period.
2.6.4. Novel Cage Test. The novel cage test was performed to
assess vertical activity, as described elsewhere [38].Mice were
introduced into a standard plastic cage the size of their home
cage filled with small amounts of fresh sawdust. The number
of exploratory rearings was counted under red light during a
5min period.
2.6.5. Open Field. The open field apparatus consisted in four
square arenas (50 cm × 50 cm × 50 cm), made of wood
covered by white Resopal. Mice were put in the center and
their behaviour was recorded on camera for 10min.The open
field was illuminated with white light (25 Lux). Distance
moved and mean instant speed were analysed off-line using
the Any-maze software (Stoelting Co., Wood Dale, IL, USA),
as described elsewhere [45].
2.6.6. Sucrose Test. Animals were given 8 hours of free choice
between two bottles of either 1% sucrose or normal drinking
water, as described elsewhere [38]. At the beginning and end
of the period, the bottles were weighed and consumption
was calculated. The beginning of the test started with the
onset of the dark (active) phase of animals’ cycle. To prevent
the possible effects of side-preference in drinking behaviour,
the position of the bottles in the cage was switched at 4
hours, halfway through testing. No previous food or water
deprivation was applied before the test. The 1% sucrose
solution is used in tests performed across the experiment.
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Figure 2: Chronic intraperitoneal injections increase depressive-like behaviour in the forced swim test. In comparison with control group,
mice that received daily intraperitoneal saline injections over the course of threeweeks had a nonsignificant reduction of the latency of floating
(a) and significant increase of the total number of floating episodes (b) and total time spent floating (c). There were no significant differences
in mean velocity (d) or distance swum (e) between control and injected groups. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01 versus control (unpaired 𝑡-test). Con:
control group (𝑛 = 7); i.p. injection: a group of mice subjected to intraperitoneal injections with a vehicle (𝑛 = 5). All data are means ± SEM.
Percentage preference for sucrose is calculated using the
following formula:
Sucrose Preference
= [
𝑉(Sucrose solution)
𝑉(Sucrose solution) + 𝑉(Water)
] × 100%.
(1)
2.6.7. Tail Suspension Test. The protocol used in this study
was adapted from a previously proposed procedure [41, 43].
Mice were subjected to the tail suspension by being hung
by their tails with adhesive tape to a rod 50 cm above the
floor for 6min. Animals were tested in a dark room where
only the area of the modified tail suspension construction
was illuminated by a spotlight from the ceiling; the lighting
intensity on the height of the mouse position was 25 Lux.The
trials were recorded by a video camera positioned directly in
front of themice while the experimenter observed the session
from a distance in a dark area of the experimental room.This
procedure was carried out twice with a 24 h interval between
tests. The latency of the first episode of immobility, the total
duration of this behaviour, and mean velocity were scored
using Noldus EthoVision XT 8.5 (Noldus Information Tech-
nology, Wageningen, Netherlands) according to the protocol
that was previously validated [41]. In accordance with the
commonly accepted criteria of immobility, the immobility
behaviour was defined as the absence of any movements of
the animals’ head and body. The latency of immobility was
determined as the time between the onset of the test and the
first bout of immobility.
2.7. Statistical Analysis. Data were analysed with GraphPad
Prism version 5.00 forWindows (SanDiego, CA, USA). Two-
tailed unpaired 𝑡-tests were applied for two-group, two-tailed
comparisons of independent data sets, as the distribution was
normal. One-way ANOVA was used followed by a post hoc
Dunnett for a comparison of more than two groups with a
control; repeated measures ANOVA was used for analysis of
repeated measures. The level of confidence was set at 95%
(𝑃 < 0.05) and data are shown as mean ± SEM.
3. Results and Discussion
3.1. Effects of 3-Week Intraperitoneal Vehicle Injections on
Floating Behaviour. Behaviour analysis revealed that animals
subjected to injections displayed a nonsignificant decrease
of latency to float as compared to control animals (Day 1:
𝑃 = 0.11, 𝑡 = 1.73; Day 2: 𝑃 = 0.91, 𝑡 = 0.12, Figure 2(a),
unpaired two-tailed 𝑡-test). The number of floating episodes
and the duration of floating in the chronically injected group
were significantly higher than in control animals (Day 1: 𝑃 =
0.0037, 𝑡 = 3.89 and 𝑃 = 0.016, 𝑡 = 3.06; Day 2: 𝑃 = 0.0016,
𝑡 = 4.30 and 𝑃 = 0.11, 𝑡 = 1.77, resp.; Figures 2(b) and 2(c),
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unpaired two-tailed 𝑡-test); mean velocity of swimming and
distance moved were nonsignificantly decreased (Day 1: 𝑃 =
0.25, 𝑡 = 1.25 and 𝑃 = 0.31, 𝑡 = 1.09; Day 2: 𝑃 = 0.18, 𝑡 =
1.43 and 𝑃 = 0.15, 𝑡 = 1.56, resp.; Figures 2(d) and
2(e), unpaired two-tailed 𝑡-test). This suggests increased
“behavioural despair,” a sign of depressive-like state, in mice
that received chronic manipulations with intraperitoneal
injections.
Similar results were obtained in our previous experiments
which demonstrated that three-and four-week daily injec-
tions in chronically stressed mice increased the number of
individuals exhibiting signs of anhedonia, a reduced sensi-
tivity to reward, in a sucrose preference test [18, 24]. Other
studies showed that chronic intraperitoneal injections in rats
evoke ultrasonic vocalizations at 22 kHz range, indicative of a
negative emotional state that was reduced by preexposure of
experimental animals to handling [16].These “prodepressive”
like changes found in this study could be potentially induced
bywell-recognized pathogenetic elements of depression, such
as stress of manipulation [46] and pain experience [47, 48]
and repeated situations of unescapable stress and helplessness
[49], as well as inflammation [50].
3.2. Effects of Chronic Imipramine Delivery via Food Pellets on
Floating Behaviours and Other Variables. In order to assess
the efficacy of an alternative chronic dosing design that could
preclude the adverse changes in behaviour described above,
we evaluated the effects of four-week dosing of imipramine
via food pellets in the forced swim test and supplementary
behavioural paradigms. Animals subjected to imipramine
treatment showed a significant increase in the latency to float
and decreased immobility time, when compared to control
animals (Day 1:𝑃 = 0.0002, 𝑡 = 5.19 and𝑃 = 0.0008, 𝑡 = 4.42;
Day 2: 𝑃 = 0.18, 𝑡 = 1.43 and 𝑃 = 0.0011, 𝑡 = 4.28, resp.;
Figure 3(a), unpaired two-tailed 𝑡-test). Thus, an applied low
dose of antidepressant treatment delivered with food pellets
induced an antidepressant-like effect in the present study.
This result is in line with our previous findings that
showed that a 3-week low dose administration of imipramine
to C57BL6J mice via drinking water reduced such depres-
sive symptoms as stress-induced decease in sucrose intake
and preference, hyperlocomotion, and elevated aggressive
behaviour [38]. Similar behavioural results were obtained in
the chronic stress depression model with CD1 mice [42] and
in a model of elderly depression in 18-month-old C57Bl6N
mice [41]. The low dose imipramine antidepressant effects
were accompanied by preservation of normal activity of brain
peroxidation enzymes which were suppressed by chronic
stress [38]. These effects are typical for antidepressant effect
manifestations induced by tricyclics in rodents [35, 51].
Further, in order to rule out potential effects of imipram-
ine administration on anxiety, locomotion, and liquid intake
that were previously reported in mice treated with this drug
at a dose of 15/mg/kg in C57BL6N mice, we performed sup-
plementary tests in all mice. In both anxiety paradigms,
dark-light box andO-maze, animals treated with imipramine
showed no significant differences in their behaviour from the
control group: in latency of the exit to the anxiety-related
areas, lit box and open arms (𝑃 = 0.94, 𝑡 = 0.08 and
𝑃 = 0.59, 𝑡 = 0.55, resp.; unpaired two-tailed 𝑡-test), time
spent in the lit box and open arms (𝑃 = 0.80, 𝑡 = 0.26
and 𝑃 = 0.28, 𝑡 = 1.14, resp.; unpaired two-tailed 𝑡-test),
and numbers of exits to these zones (𝑃 = 0.87, 𝑡 = 0.17
and 𝑃 = 0.13, 𝑡 = 1.63, resp.; unpaired two-tailed 𝑡-test,
Figures 3(b) and 3(c)). In locomotory tests, in comparison
with controlmice, animals treatedwith imipramine exhibited
normal vertical activity, as shown by the number of rearings
in novel cage (Week 2: 𝑃 = 0.33, 𝑡 = 1.01; Week 4: 𝑃 = 0.54,
𝑡 = 0.63, unpaired two-tailed 𝑡-test), as well as unchanged
horizontal locomotion in the open field. In the latter test, no
difference between groups was found in distance travelled
(Week 2: 𝑃 = 0.97, 𝑡 = 0.038; Week 4: 𝑃 = 0.31, 𝑡 = 1.05)
or mean instant velocity (Week 2: 𝑃 = 0.98, 𝑡 = 0.026;
Week 4: 𝑃 = 0.84, 𝑡 = 0.21; Figure 3(d), unpaired two-tailed
𝑡-test). In a two-bottle sucrose preference test, there were
no significant differences in water intake, sucrose solution
intake, and sucrose preference between the groups (𝑃 = 0.47,
𝑡 = 0.75; 𝑃 = 0.32, 𝑡 = 1.04; 𝑃 = 0.20, 𝑡 = 1.35, resp.;
unpaired two-tailed 𝑡-test, Figure 3(e)). Finally, body weight
was not different between control and imipramine-treated
groups (𝑃 = 0.20, 𝑡 = 1.37, data not shown, unpaired two-
tailed 𝑡-test).There is no statistical significance using repeated
measures ANOVA (data not shown).
Thus, the employed dosing with imipramine did not
affect basic physiological variables, such as locomotion, liquid
consumption, and body weight. Also, it did not affect the
parameters of anxiety and sucrose ingestion, as reported in
some studies that employ higher amounts of tricyclics [6,
31, 52, 53]. These results suggest that low dose imipramine
treatment via voluntary food pellet intake can serve as
an optimal pharmacological reference in animal models of
depression that require prolonged antidepressant treatment
of small rodents.
3.3. Effects of Chronic Delivery via Food Pellets of New
Candidates to Antidepressants in the Forced Swim and Tail
Suspension Tests. Next, we sought to investigate whether the
defined method of antidepressant dosing with food pellets
can be applicable with the testing of new drug candidates, one
of which, celecoxib, is not soluble in water and, therefore, is
problematic to deliver to the animals chronically. As such, we
exposed a cohort of animals to food pellets containing new
drug candidates: dicholine succinate or celecoxib. In addition,
we used imipramine or citalopram as the antidepressant
references.
In the forced swim test, one-way ANOVA revealed signif-
icant differences between the groups in the latency to float,
total time spent floating, and velocity (Day 1: 𝑃 = 0.0054,
𝐹 = 4.24; 𝑃 = 0.049, 𝐹 = 2.60; and 𝑃 = 0.22, 𝐹 = 3.18,
resp., Figure 4(a)). Post hoc Dunnett test showed that, on
Day 1, in comparison with the control group, the latency to
swim was increased in animals treated with imipramine or
dicholine succinate (𝑃 < 0.05, 𝑞 = 3.17 and 𝑃 < 0.01,
𝑞 = 3.20), the duration of immobility was decreased in
the imipramine-treated animals (𝑃 < 0.05, 𝑞 = 2.67), and
velocity was elevated in the dicholine succinate-treated group
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Figure 3: Effects of dosing with imipramine via food pellets on floating scores and other behaviours. (a) In comparison with control group,
mice that received imipramine in food pellets over four weeks showed an increase of latency to float and total duration of floating in the forced
swim test. No significant differences between the groups were found in parameters of anxiety (b) in the dark-light box and (c) O-maze tests.
(d) Control and imipramine-treated mice showed similar numbers of rearings in the novel cage, distance travelled, and mean velocity in the
open field test. (e) In the two-bottle sucrose preference test, water intake, sucrose solution intake, and sucrose preference were not different
between imipramine-treated and control groups. ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001 versus control (unpaired 𝑡-test). Con: control group (𝑛 = 7);
Imi-food: imipramine-treated group (𝑛 = 8). All data are means ± SEM.
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Figure 4: Effects of chronic delivery via food pellets of new candidates to antidepressants in the forced swim and tail suspension tests. (a) On
Day 1 of the forced swim test, as compared with control, imipramine-treated animals elicited an increase in latency to float and reduced time
spent floating, and dicholine succinate-treated groups displayed an increased swim velocity. (b)OnDay 2 of the forced swim test, imipramine-
treated group had higher latency to float in comparison to control mice; no other differences between treated and control groups were found.
(c) OnDay 1 of the tail suspension test, there was a significant increase of the latency of immobility and velocity in imipramine- and dicholine
succinate-treated groups, as compared to controls. All treated groups showed a significant reduction of total time spent immobile, as compared
to control animals. (d) OnDay 2 of the tail suspension test, in comparison to control group, an increase of the latency of immobility was found
in imipramine-treated group and an increase of velocity was observed in both imipramine- and dicholine succinate-treated mice. All animals
that received a treatment demonstrated a significant reduction of total time spent immobile, in comparison to control group. ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 versus control (one-way ANOVA with Dunnett post hoc tests). All groups were 𝑛 = 10. Con: control group;
Imi-food: imipramine-treated group; Cit-food: citalopram-treated group; DS-food: dicholine succinate-treated group; Cel-food: celecoxib-
treated group. All data are means ± SEM.
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(𝑃 < 0.05, 𝑞 = 2.62). On Day 2 of the forced swim test,
one-way ANOVA showed a trend to a statistically significant
difference in the latency of floating and no differences in
the duration of floating or velocity (𝑃 = 0.059, 𝐹 = 2.46;
𝑃 = 0.48, 𝐹 = 0.89; and 𝑃 = 0.40, 𝐹 = 1.04, resp.,
Figure 4(b)). Dunnett post hoc test revealed a significant
increase in latency to float in the imipramine-treated group
(𝑃 < 0.05; 𝑞 = 2.96). As a reduction of the parameters of
floating behaviour in the forced swim test is awell-established
measure of antidepressant activity of various compounds
[32, 35], these data suggest that the applied treatment with
imipramine or dicholine succinate induces an antidepressant
effect and that the employed dosing was effective.
With the tail suspension test, one-way ANOVA showed
that, on Day 1, there were statistically significant differences
between the groups in the latency and duration of immobility
(𝑃 = 0.007, 𝐹 = 4.09; 𝑃 < 0.0001, 𝐹 = 3.43; and 𝑃 <
0.0001, 𝐹 = 3.43, resp., Figure 4(c)); a strong tendency to
differences in velocity was found (𝑃 = 0.0505, 𝐹 = 2.57).
Post hoc Dunnett test revealed a significant difference in the
latency of immobility from the control group in imipramine-
treated animals (𝑃 < 0.01, 𝑞 = 3.380) but not in other treat-
ment groups. All groups that received pharmacological treat-
ment had significantly reduced duration of immobility in
comparison to control mice (imipramine-treated: 𝑃 < 0.001,
𝑞 = 4.50; citalopram-treated: 𝑃 < 0.001, 𝑞 = 5.02; dicholine
succinate-treated: 𝑃 < 0.05, 𝑞 = 3.07; celecoxib-treated:
𝑃 < 0.05, 𝑞 = 2.65; Dunnett test). In comparison to control
group, velocity was significantly increased in imipramine-
and dicholine succinate-treated groups (𝑃 < 0.05, 𝑞 = 2.55;
𝑃 < 0.05, 𝑞 = 2.56, resp.; Dunnett test).
On Day 2 of the tail suspension test, statistically signifi-
cant differences between the groups were found in the latency
of immobility, the duration of immobility, and velocity (𝑃 =
0.0159, 𝐹 = 3.43; 𝑃 < 0.0002, 𝐹 = 6.90; and 𝑃 = 0.012,
𝐹 = 3.65, resp., one-way ANOVA; Figure 4(d)). Dunnett
post hoc test showed a significant increase of the latency of
immobility in imipramine- and dicholine succinate-treated
animals, as compared with controls (𝑃 < 0.01, 𝑞 = 3.48 and
𝑃 < 0.05, 𝑞 = 2.75, resp.). All treated groups had significantly
reduced duration of immobility, as compared with control
mice (imipramine-treated: 𝑃 < 0.001, 𝑞 = 4.46; citalopram-
treated: 𝑃 < 0.001, 𝑞 = 4.31; dicholine succinate-treated:
𝑃 < 0.01, 𝑞 = 3.39; celecoxib-treated: 𝑃 < 0.001, 𝑞 = 4.24;
Dunnett test). Velocity was significantly increased in com-
parison with control mice in the imipramine- and dicholine
succinate-treated groups (𝑃 < 0.05, 𝑞 = 2.97; 𝑃 < 0.05,
𝑞 = 2.59, resp.; Dunnett test). Since a decrease of immobility
behaviour in the tail suspension test is generally considered
as a manifestation of the antidepressant activity of various
treatments [32, 54], these results evidence an antidepressant-
like effect of the applied drugs and again the efficacy of the
tested method of drug administration.
4. Conclusions
Thus, as a desirable alternative to invasive dosing, such
as chronic intraperitoneal injections, the administration of
various drugs via food pellets can be very efficient.The results
from our study are in line with other successful attempts to
avoid adverse drug delivery methodologies in translational
research that showed, for example, the efficacy of treatment
with analgesic therapy delivered via food in rats which were
subjected to surgery [55]. The use of such methods could
be particularly needed when repeated drug administration
to stressed, operated, or immunodeficient laboratory animals
is necessary and therefore could greatly improve not only
animal welfare but also the validity of animal models.
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